Miraculins has received a grant of $100,000 from the Manitoba Technology Commercialization Program (TCP) to support the commercialization of the PreVu non-invasive cholesterol test.
The company’s PreVu test is a coronary artery disease (CAD) risk assessment technology that measures cholesterol levels in a patient’s skin non-invasively, painlessly and without the need for fasting.
High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, carotid intima media thickness, inflammatory markers of vascular disease, previous heart attack incidents and Framingham risk score.
Miraculins president and CEO Christopher Moreau said PreVu has been designed to provide new information, in addition to existing risk factors, to determine a person’s risk of suffering a heart attack and they look forward to make this tool available to patients as well as medical and healthcare professionals.